• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

ECULIZUMAB

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

AGING CD4 ACE2 PSEUDOMONAS AERUGINOSA COGNITION INFLAMMATORY RESPONSE CELL PROLIFERATION PD-1 CANDIDA ALBICANS STAPHYLOCOCCUS AUREUS TMPRSS2 INTERFERON IMMUNE RESPONSE ALBUMIN IL10 ESCHERICHIA COLI NFKB1 LACTATE DEHYDROGENASE IL6 CELL DIFFERENTIATION RHEUMATOID ARTHRITIS IMMUNITY ANGIOTENSIN II HELICOBACTER PYLORI PARKINSON DISEASE TNF METFORMIN IL2 IFNG AUTOPHAGY CASP3 LISTERIA MONOCYTOGENES RAS ACE COAGULATION MYALGIA APOPTOTIC PROCESS IL1B INFLAMMATION CANCER ALZHEIMER'S DISEASE COVID-19 NEUTROPHILS SARS-COV-2 INSULIN

© 2021 Biovista Vizit All Rights Reserved.